Patients with Barrett's Esophagus will be enrolled. The intervention is cessation of acid-suppressing medications. Biopsies will be taken during endoscopy at Day 0, 7, and 14.

Barrett's Esophagus

Gastroesophageal Reflux Disease

Acid suppressing medications are stopped for all participants the day after baseline assessment. Subsequent evaluations are performed while the participant is not on acid-suppressing medications. Endoscopy with biopsies will be performed in all patients on day 0, 7, and 14.

Cessation of Acid Suppressing Medications

Dallas VA Medical Center

Reflux-Induced Oxidative Stress in Barrett's Esophagus: Response, Repair, and Epithelial-Mesenchymal-Transition

Inflammation of the esophageal mucosa will be measured at baseline and at 14 days. Esophageal mucosal inflammation will be measured using esophageal mucosal biopsy specimens, and histopatholgical grading. Mucosal infiltration with inflammatory cells (neutrophils, eosinophils, and lymphocytes) will be measured.

p38 and components of the p38 pathway will be measured in the esophageal mucosa at baseline and at 14 days

phospho-p38 will be measured in the esophageal mucosa at baseline, day 7, and at day 14

OxiSelect Oxidative DNA Damage ELISA assay of Barrett's mucosa at baseline, day 7, and day 14

VEGF will be measured in the esophageal mucosa at baseline and at day 14

APE-1 will be measured in the esophageal mucosa at baseline, day 7, and at day 14

NPM-1 will be measured in the esophageal mucosa at baseline, day 7, and at day 14

phospho-NPM1 will be measured in the esophageal mucosa at baseline, day 7, and at day 14

Stuart Spechler

Professor of Medicine

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Patients with reflux and a prior history of reflux esophagitis are being enrolled. The intervention is cessation of acid-suppressing medications.

Esophagitis

Reflux Esophagitis

Acid-suppressing medications are stopped for all participants the day after baseline assessment. Subsequent evaluations performed while participant is not on acid-suppressing medications.

The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis

inflammation of the squamous esophageal mucosa will be measured at baseline and at 14 days

Amount of HIF-2a present will be measured at baseline and at 14 days

Patients undergo radiotherapy QD 5 days a week for 30 fractions. Patients also receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes once weekly for 6 weeks. Patients undergo FDG-PET/CT imaging between fractions 18 and 19.

Patients undergo an individualized dose of image-guided radiotherapy QD 5 days a week for 30 fractions and undergo 18 F FDG-PET/CT between fractions 18 and 19. Based on the scan results, patients undergo individualized adaptive radiotherapy for the final 9 fractions. Patients also receive paclitaxel and carboplatin as in Arm I.

Stage III Lung Non-Small Cell Cancer AJCC v7

Stage IIIA Lung Non-Small Cell Cancer AJCC v7

Stage IIIB Lung Non-Small Cell Cancer AJCC v7

Undergo FMISO PET/CT (Correlative studies)

18F-Fluoromisonidazole

Carboplatin

Computed Tomography

External Beam Radiation Therapy

Fludeoxyglucose F-18

Undergo individualized adaptive radiotherapy

Image-Guided Adaptive Radiation Therapy

Laboratory Biomarker Analysis

Paclitaxel

Positron Emission Tomography

Stanford Cancer Institute Palo Alto

Augusta University Medical Center

Rush University Medical Center

Indiana University/Melvin and Bren Simon Cancer Center

The James Graham Brown Cancer Center at University of Louisville

University of Michigan Comprehensive Cancer Center

University of Mississippi Medical Center

Saint Luke's Hospital of Kansas City

Washington University School of Medicine

Memorial Sloan Kettering Basking Ridge

Memorial Sloan Kettering Commack

Memorial Sloan Kettering Westchester

Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Sleepy Hollow

Memorial Sloan Kettering Nassau

Case Western Reserve University

Cleveland Clinic Cancer Center/Fairview Hospital

Cleveland Clinic Foundation

Cleveland Clinic Cancer Center Independence

Hillcrest Hospital Cancer Center

Cleveland Clinic Cancer Center Strongsville

Cleveland Clinic Wooster Family Health and Surgery Center

University of Oklahoma Health Sciences Center

Fox Chase Cancer Center

Temple University Hospital

Reading Hospital

Medical University of South Carolina

University of Wisconsin Hospital and Clinics

Medical College of Wisconsin

McGill University Department of Oncology

Saskatoon Cancer Centre

Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer

Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

National Cancer Institute (NCI)

NRG Oncology

The subject with positive breath Test for H.pylori and/or positive stool antigen test

The subject with negative breath Test for H.pylori and negative stool antigen test

esophagitis/hypoxia

Reflux-Induced Oxidative Stress in Barrett's Esophagus: Response, Repair, and Epithelial-Mesenchymal-Transition

The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis

Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer

An Investigation of the Association Between Helicobacter Pylori Infection and Abdominal Pain in Cystic Fibrosis Patients

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen